Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 199

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 199
---
 $
        52

        Right-of-use lease liabilities, noncurrent

        67

        91

        Total finance lease liabilities
         
        $
        122

        $
        143

        Weighted average remaining lease term

        Operating leases
         
        2.5 years

        3.5 years

        Finance leases
         
        2.4 years

        3.0 years

        Weighted average discount rate

        Operating leases

        6.4
        %

        6.5
        %

        Finance leases

        7.1
        %

        6.9
        %

127

Future minimum lease commitments are as follows as of December 31, 2024 (in thousands): 

        Operating Leases

        Finance Leases

        Year Ending December 31,

        2025
         
        $
        1,178

        $
        64

        2026

        738

        39

        2027

        685

        29

        Total lease payments

        2,601

        132

        Less imputed interest

        (209
        )

        (10
        )

        Total
         
        $
        2,392

        $
        122

       Operating lease expense was $1.1 million for the twelve months ended December 31, 2024 and 2023, respectively.CollaborationsRoche AgreementIn December 2021, Lineage entered into the Roche Agreement, wherein Lineage granted to Roche exclusive worldwide rights to develop and commercialize RPE cell therapies, including Lineage’s proprietary cell therapy known as OpRegen, for the treatment of ocular disorders, including GA secondary to AMD.Under the terms of the Roche Agreement, Roche paid Lineage a $50.0 million upfront payment and Lineage is eligible to receive up to an additional $620.0 million in developmental, regulatory and commercialization milestone payments. Lineage also is eligible for tiered double-digit percentage royalties on net sales of OpRegen in the U.S. and other major markets. All regulatory and commercial milestone payments and royalty payments are subject to the existence of certain intellectual property rights that cover OpRegen at the time such payments would otherwise become due, and the royalty payments on net sales of OpRegen are subject to financial offsets based on the existence of